Abstract:Yihan Wang, 1, 2 Yizhen Wei, 1, 2 Yichun Wu, 1, 2 Yue Zong, 1, 2 Yingying Song, 2 Shengyan Pu, 2 Wenwen Wu, 2 Yun Zhou, 1 Jun Xie, 2 Haitao Yin 1 1 Department of Radiotherapy Central Hospital, Affiliated Xuzhou Clinical College of Xuzhou Medical University, Xuzhou, 221009, People's Republic of China; 2 Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, 221116, People's Republic of China Correspondence: Haitao Yin; Jun Xie, Email ; Purpose: Realgar, as a kind of traditional mineral Chinese medicine, can inhibit multiple solid tumor growth and serve as an adjuvant drug in cancer therapy. However, the extremely low solubility and poor body absorptive capacity limit its application in clinical medicine. To overcome this therapeutic hurdle, realgar can here be fabricated into a nano-realgar hydrogel with enhanced chemotherapy and radiotherapy (RT) ability. Our objective is to evaluate the superior biocompatibility and anti-tumor activity of nano-realgar hydrogel. Methods: We have successfully synthesized nano-realgar quantum dots (QDs) coupling with 6-AN molecules (NRA QDs) and further encapsulated with a pH-sensitive dextran hydrogel carrier with hyaluronic acid coating (DEX-HA gel) to promote bioavailability, eventually forming a multifunctional nano-realgar hydrogel ( Gel). To better investigate the tumor therapy efficiency of the Gel, we have established the mice in situ bearing GL261 brain glioblastoma as animal models assigned to receive intratumor injection of Gel. Results: The designed Gel as an antitumor drug can not only exert the prominent chemotherapy effect but also as a "sustainable reactive oxygen species (ROS) generator" can inhibit in the pentose phosphate pathway (PPP) metabolism and reduce the production of nicotinamide adenine dinucleotide phosphate (NADPH), thereby inhibiting the conversion of glutathione disulfide (GSSG) to glutathione (GSH), reducing GSH concentrations in tumor cells, triggering the accumulation of ROS, and finally enhancing the effectiveness of RT. Conclusion: Through the synergistic effect of chemotherapy and RT, Gel effectively inhibited the proliferation and migration of tumor cells, suppressed tumor growth, improved motor coordination, and prolonged survival in tumor-bearing mice. Our work aims to improve the Gel-mediated synergistic chemotherapy and RT will endow a "promising future" for the old drug in clinically comprehensive applications. Keywords: Gel, glioma, inhibition of the PPP, ROS, radiosensitization, synergistic therapy Brain gliomas are the most common and fatal primary tumors among central nervous system malignancies. The standard of care is surgical resection followed by radiotherapy (RT) and chemotherapy, but the prognosis is extremely poor 1,2 Clinical chemotherapeutic drugs are typically associated with common limiting features, including a single variety, poor targeting, high doses, strong toxicity, and significant side effects that are not easily tolerated. Conventional fractionated radiotherapy (RT) is often applied in clinical practice. However, it is prone to radiation-induced brain injuries, such as vasodilatation, blood–brain barrier impairment, leucoencephalopathy, and radiation necrosis. 3–5 Additionally, the hypoxic environment of tumors and the removal of reactive oxygen species (ROS) produced by intracellular antioxidants can cause radiochemotherapy resistance and reduce the corresponding efficacy. 6–8 The tumor microenvironment can be characterised by low pH, hypoxia, high concentrations of glutathione (GSH), and specific expression of enzymes. As a vital component of the antioxidant system, GSH scavenges ROS in the body. However, stabilisation of the redox state is destroyed by the consumption of GSH, resulting in ROS accumulation. Under the action of nicotinamide adenine dinucleotide phosphate (NADPH), glutathione disulfide (GSSG) can be converted into GSH, which is a source of intracellular GSH. Therefore, NADPH is essential for the reduction process. A competitive inhibitor of 6-Phosphogluconate Dehydrogenase (G6PDH) is 6-Aminonicotinamide (6-AN), which is a key enzyme in the pentose phosphate pathway. NADPH production is reduced by the inhibition of the pentose phosphate pathway (PPP), thereby blocking the conversion of GSSG to GSH. 9–12 Reducing intracellular GSH level is beneficial for many cancer therapeutic regimens. In the past few years, with the rapid development of nanotechnology, the use of nanotechnology has been considered as a promising strategy to imp -Abstract Truncated-

A Big Prospect for Hydrogel Nano-System in Glioma

Tumor Microenvironment Targeting System for Glioma Treatment Via Fusion Cell Membrane Coating Nanotechnology.

Hydrogel Applications in the Diagnosis and Treatment of Glioblastoma

An injectable in situ hydrogel platform for sustained drug release against glioblastoma

Multifunctional Nano-Realgar Hydrogel for Enhanced Glioblastoma Synergistic Chemotherapy and Radiotherapy: A New Paradigm of an Old Drug

Exth-28. Developing A Novel Injectable Immunotherapeutic Gel For Encapsulation Of Natural Killer Cells For Post-Surgical Glioblastoma Treatment

Biodegradable SPI-based hydrogel for controlled release of nanomedicines: A potential approach against brain tumors recurrence

Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence

Hydrogel-Based Drug Delivery Nanosystems for the Treatment of Brain Tumors

Combined Biomimetic MOF-RVG15 Nanoformulation Efficient Over BBB for Effective Anti-Glioblastoma in Mice Model

Lymph node-inspired immunoregulatory hydrogel with siRNA delivery property for postoperative glioblastoma treatment

Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors

Advances in Hydrogels of Drug Delivery Systems for the Local Treatment of Brain Tumors

Hydrogel loading functionalized PAMAM/shRNA complex for postsurgical glioblastoma treatment

A Nanogel with Effective Blood-Brain Barrier Penetration Ability through Passive and Active Dual-Targeting Function

Assembled Embedded 3D Hydrogel System for Asynchronous Drug Delivery to Inhibit Postoperative Recurrence of Malignant Glioma and Promote Neurological Recovery

Thermoresponsive Nanocomposite Gel for Local Drug Delivery to Suppress the Growth of Glioma by Inducing Autophagy

Injectable pH Thermo-Responsive Hydrogel Scaffold for Tumoricidal Neural Stem Cell Therapy for Glioblastoma Multiforme

A Gambogic Acid-Loaded Delivery System Mediated by Ultrasound-Targeted Microbubble Destruction: A Promising Therapy Method for Malignant Cerebral Glioma